| CPC C12N 5/0657 (2013.01) [C12N 5/0696 (2013.01); C12N 2500/46 (2013.01); C12N 2500/50 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01); C12N 2513/00 (2013.01); C12N 2533/52 (2013.01); C12N 2533/54 (2013.01); C12N 2537/10 (2013.01)] | 20 Claims |
|
1. A method of screening a candidate compound or substance for an effect on cardiac tissue, the method comprising:
forming a biomimetic-PSC suspension by suspending a population of pluripotent stem cells (PSCs) in a covalently crosslinkable component and a natural hydrogel component, the natural hydrogel component comprising one or more of fibrinogen, collagen, gelatin, hyaluronic acid, elastin, fibronectin, laminin, fibrin, alginate, and decellularized cardiac extracellular matrix;
crosslinking the biomimetic-PSC suspension to produce a three-dimensional biomimetic PSC microenvironment;
culturing the three-dimensional biomimetic-PSC microenvironment to differentiate the three-dimensional biomimetic-PSC microenvironment into a three-dimensional, synchronously contracting cardiac tissue;
exposing the cardiac tissue to a candidate compound or substance; and
determining an effect of the candidate compound or substance on the cardiac tissue.
|